Literature DB >> 23468189

Benzenesulfonamides: a unique class of chemokine receptor type 4 inhibitors.

Suazette Reid Mooring1, Jin Liu, Zhongxing Liang, Jeffrey Ahn, Samuel Hong, Younghyoun Yoon, James P Snyder, Hyunsuk Shim.   

Abstract

The interaction of CXCR4 with CXCL12 (SDF-1) plays a critical role in cancer metastasis by facilitating the homing of tumor cells to metastatic sites. Based on our previously published work on CXCR4 antagonists, we have synthesized a series of aryl sulfonamides that inhibit the CXCR4/CXCL12 interaction. Analogue bioactivities were assessed with binding affinity and Matrigel invasion assays. Computer modeling was employed to evaluate a selection of the new analogues docked into the CXCR4 X-ray structure and to rationalize discrepancies between the affinity and Matrigel in vitro assays. A lead compound displays nanomolar potency in the binding affinity assay (IC(50)=8.0 nM) and the Matrigel invasion assay (100 % blockade of invasion at 10 nM). These data demonstrate that benzenesulfonamides are a unique class of CXCR4 inhibitors with high potency.
Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23468189      PMCID: PMC3752296          DOI: 10.1002/cmdc.201200582

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  34 in total

1.  CXC chemokine receptor-4 antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models.

Authors:  Younghyoun Yoon; Zhongxing Liang; Xin Zhang; Mison Choe; Aizhi Zhu; Heidi T Cho; Dong M Shin; Mark M Goodman; Zhuo Georgia Chen; Hyunsuk Shim
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

2.  Unique ligand binding sites on CXCR4 probed by a chemical biology approach: implications for the design of selective human immunodeficiency virus type 1 inhibitors.

Authors:  Won-Tak Choi; Shaomin Tian; Chang-Zhi Dong; Santosh Kumar; Dongxiang Liu; Navid Madani; Jing An; Joseph G Sodroski; Ziwei Huang
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

3.  Allosteric binding sites on muscarinic acetylcholine receptors.

Authors:  Jürgen Wess
Journal:  Mol Pharmacol       Date:  2005-09-23       Impact factor: 4.436

4.  CTACK, a skin-associated chemokine that preferentially attracts skin-homing memory T cells.

Authors:  J Morales; B Homey; A P Vicari; S Hudak; E Oldham; J Hedrick; R Orozco; N G Copeland; N A Jenkins; L M McEvoy; A Zlotnik
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

Review 5.  Chemokines and cancer.

Authors:  Albert Zlotnik
Journal:  Int J Cancer       Date:  2006-11-01       Impact factor: 7.396

6.  Silencing of CXCR4 blocks breast cancer metastasis.

Authors:  Zhongxing Liang; Younghyoun Yoon; John Votaw; Mark M Goodman; Larry Williams; Hyunsuk Shim
Journal:  Cancer Res       Date:  2005-02-01       Impact factor: 12.701

Review 7.  Stereoelectronic substituent effects.

Authors:  Henrik Helligsø Jensen; Mikael Bols
Journal:  Acc Chem Res       Date:  2006-04       Impact factor: 22.384

8.  Atypical muscarinic allosteric modulation: cooperativity between modulators and their atypical binding topology in muscarinic M2 and M2/M5 chimeric receptors.

Authors:  Christian Tränkle; Andreas Dittmann; Uwe Schulz; Oliver Weyand; Stefan Buller; Kirstin Jöhren; Eberhard Heller; Nigel J M Birdsall; Ulrike Holzgrabe; John Ellis; Hans Dieter Höltje; Klaus Mohr
Journal:  Mol Pharmacol       Date:  2005-09-12       Impact factor: 4.436

9.  CASTp: computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues.

Authors:  Joe Dundas; Zheng Ouyang; Jeffery Tseng; Andrew Binkowski; Yaron Turpaz; Jie Liang
Journal:  Nucleic Acids Res       Date:  2006-07-01       Impact factor: 16.971

10.  Human G protein-coupled receptor GPR-9-6/CC chemokine receptor 9 is selectively expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine-mediated chemotaxis.

Authors:  B A Zabel; W W Agace; J J Campbell; H M Heath; D Parent; A I Roberts; E C Ebert; N Kassam; S Qin; M Zovko; G J LaRosa; L L Yang; D Soler; E C Butcher; P D Ponath; C M Parker; D P Andrew
Journal:  J Exp Med       Date:  1999-11-01       Impact factor: 14.307

View more
  10 in total

1.  Synthesis of pyridine derivatives as potential antagonists of chemokine receptor type 4.

Authors:  Suazette Reid Mooring; Theresa Gaines; Zhongxing Liang; Hyunsuk Shim
Journal:  Heterocycl Comm       Date:  2014-05       Impact factor: 1.120

2.  A benzenesulfonamide derivative as a novel PET radioligand for CXCR4.

Authors:  Yoon Hyeun Oum; Dinesh Shetty; Younghyoun Yoon; Zhongxing Liang; Ronald J Voll; Mark M Goodman; Hyunsuk Shim
Journal:  Bioorg Med Chem       Date:  2019-11-30       Impact factor: 3.641

Review 3.  Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy.

Authors:  Weiqiang Zhou; Shanchun Guo; Mingli Liu; Matthew E Burow; Guangdi Wang
Journal:  Curr Med Chem       Date:  2019       Impact factor: 4.530

4.  Anti-inflammatory hybrids of secondary amines and amide-sulfamide derivatives.

Authors:  Renren Bai; Jian Sun; Zhongxing Liang; Younghyoun Yoon; Eric Salgado; Amber Feng; Yoonhyeun Oum; Yuanyuan Xie; Hyunsuk Shim
Journal:  Eur J Med Chem       Date:  2018-03-02       Impact factor: 6.514

5.  Novel anti-inflammatory agents targeting CXCR4: Design, synthesis, biological evaluation and preliminary pharmacokinetic study.

Authors:  Renren Bai; Zhongxing Liang; Younghyoun Yoon; Eric Salgado; Amber Feng; Saumya Gurbani; Hyunsuk Shim
Journal:  Eur J Med Chem       Date:  2017-05-10       Impact factor: 6.514

6.  Symmetrical bis-tertiary amines as novel CXCR4 inhibitors.

Authors:  Renren Bai; Zhongxing Liang; Younghyoun Yoon; Shuangping Liu; Theresa Gaines; Yoonhyeun Oum; Qi Shi; Suazette Reid Mooring; Hyunsuk Shim
Journal:  Eur J Med Chem       Date:  2016-04-19       Impact factor: 6.514

7.  Development of CXCR4 modulators based on the lead compound RB-108.

Authors:  Renren Bai; Xiaokang Jie; Jian Sun; Zhongxing Liang; Younghyoun Yoon; Amber Feng; Yoonhyeun Oum; Wenyan Yu; Rui Wu; Bin Sun; Eric Salgado; Yuanyuan Xie; Hyunsuk Shim
Journal:  Eur J Med Chem       Date:  2019-04-05       Impact factor: 6.514

8.  Development of CXCR4 modulators by virtual HTS of a novel amide-sulfamide compound library.

Authors:  Renren Bai; Qi Shi; Zhongxing Liang; Younghyoun Yoon; Yiran Han; Amber Feng; Shuangping Liu; Yoonhyeun Oum; C Chris Yun; Hyunsuk Shim
Journal:  Eur J Med Chem       Date:  2016-11-24       Impact factor: 6.514

9.  Anti-HIV small-molecule binding in the peptide subpocket of the CXCR4:CVX15 crystal structure.

Authors:  Bryan D Cox; Anthony R Prosser; Brooke M Katzman; Ana A Alcaraz; Dennis C Liotta; Lawrence J Wilson; James P Snyder
Journal:  Chembiochem       Date:  2014-07-02       Impact factor: 3.164

10.  Discovery of novel aminopiperidinyl amide CXCR4 modulators through virtual screening and rational drug design.

Authors:  Yoon Hyeun Oum; Steven A Kell; Younghyoun Yoon; Zhongxing Liang; Pieter Burger; Hyunsuk Shim
Journal:  Eur J Med Chem       Date:  2020-06-06       Impact factor: 6.514

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.